Multi-Omics Advances in Major Depressive Disorder for Molecular Insights, Biomarker Discovery, and Therapeutic Development
aging and disease · 2025
DOI: 10.14336/ad.2025.1075 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift aging and disease, 2025. Verfasst von Abdelbaset Mohamed Elasbali und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Science, College of Applied Medical Sciences-Qurayyat, Jouf University, Sakakah, Saudi Arabia. Hauptthemen laut MEDLINE: Major Depressive Disorder, Antidepressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Major depressive disorder (MDD) affects hundreds of millions worldwide and remains a major unmet clinical need because conventional monoaminergic agents achieve remission in fewer than half of patients and leave a substantial treatment-resistant subgroup. To address this gap, integrative multi-omics approaches, combined with computational systems biology, are being used to dissect its multifactorial etiology. Here, we review key findings from large Genome-wide association studies (GWAS), single-cell and spatial transcriptomics, proteomics, and metabolomics that converge on disrupted neuroplasticity, immune-inflammatory signaling, HPA-axis dysregulation, mitochondrial metabolism, and gut-brain interactions. We describe how AI-driven network modeling and structure-based drug design (SBDD) are translating multi-omics signals into candidate biomarkers and mechanism-based therapeutics, for example, N-methyl-D-aspartate/glutamatergic modulators, kappa opioid antagonists, anti-inflammatory agents, and epigenetic modulators. We highlighted the clinical implications, specifically molecularly stratified biomarkers for patient selection, trial enrichment, and structure-guided optimization of rapid-acting antidepressants and microbiome-based interventions. Finally, we discuss the limitations and immediate translational priorities that emphasize the trajectory from multi-omics discovery to precision psychiatry for MDD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory Science, College of Applied Medical Sciences-Qurayyat, Jouf University, Sakakah, Saudi Arabia.
- King Salman Center for Disability Research, Riyadh 11614, Saudi Arabia.
- Department of Biology, College of Science, University of Ha'il, Ha'il, Saudi Arabia.
- Department of Physical Therapy and Health Rehabilitation, College of Applied Medical Sciences, Jouf University, Al-Qurayyat, Saudi Arabia.
- Centre of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.
- Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India.
Zitieren
APA
Elasbali, A. M., Adnan, M., Ali, A. S., Shamsi, A., & Hassan, M. I. (2025). Multi-Omics Advances in Major Depressive Disorder for Molecular Insights, Biomarker Discovery, and Therapeutic Development. aging and disease. https://doi.org/10.14336/ad.2025.1075
Vancouver
Elasbali AM, Adnan M, Ali AS, Shamsi A, Hassan MI. Multi-Omics Advances in Major Depressive Disorder for Molecular Insights, Biomarker Discovery, and Therapeutic Development. aging and disease. 2025. doi:10.14336/ad.2025.1075
BibTeX
@article{Elasbali2025,
author = {Elasbali, Abdelbaset Mohamed and Adnan, Mohd and Ali, Ahmed S and Shamsi, Anas and Hassan, Md Imtaiyaz},
title = {Multi-Omics Advances in Major Depressive Disorder for Molecular Insights, Biomarker Discovery, and Therapeutic Development},
journal = {aging and disease},
year = {2025},
doi = {10.14336/ad.2025.1075}
}
EUVIMED